GO
Loading...

Allergan Inc

More

  • TIMELINE-Ackman and Valeant maneuver for Allergan Tuesday, 1 Jul 2014 | 2:02 PM ET

    July 1- Valeant Pharmaceuticals International Inc has teamed up with Pershing Square Capital Management, led by activist investor William Ackman, to make a run at Botox maker Allergan Inc. Here are the details of some of the most interesting steps along the way.

  • NEW YORK and LOS ANGELES, July 1- Allergan Inc may take on debt to buy back its own shares as part of a multi-faceted plan to thwart a $53 billion takeover bid by Valeant Pharmaceuticals International Inc and activist investor William Ackman.

  • NEW YORK, June 30- Most investments came up winners in the first half of 2014, which came to a close on Monday with solid gains for U.S. stocks, U.S. Treasuries, muni bonds, oil and gold. Forest Labs +64.9 Keurig Green +65.0.

  • June 30- Allergan Inc said on Monday that the U.S. Food and Drug Administration would not approve its acute migraine aerosol treatment until certain concerns are addressed, but the agency approved a new use for its implantable eye drug, Ozurdex.

  • Midday movers: Allergan, MBIA, Treehouse Foods & More Monday, 30 Jun 2014 | 12:13 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Monday's midday movers:

  • Hope you owned these 11 stocks this quarter Monday, 30 Jun 2014 | 9:57 AM ET
    Traders work the floor of the New York Stock Exchange.

    From oil exploration to online video, see 11 stocks that did exceptionally well over the last few months. USAToday reports.

  • June 30- Allergan Inc said on Monday the U.S. Food and Drug Administration had raised issues about its application for a new acute migraine aerosol but had separately approved a treatment for diabetic macular edema.

  • June 30- Allergan Inc on Monday said the U.S. Food and Drug Administration had raised issues about its application for a new acute migraine treatment and that it was working with the agency to address them.

  • Let's make a deal! Global M&A at 7-year high Monday, 30 Jun 2014 | 6:21 AM ET
    Viagra made by Pfizer and Nexiam made by AstraZeneca.

    Investor support for large acquisitions and a desire to trump rivals in consolidating markets have led CEOs to strike big transactions in 2014.

  • NEW YORK, June 30- Investor support for large acquisitions and a desire to trump rivals in consolidating markets have led chief executives to strike big transactions so far in 2014, raising year-to-date global deal volumes to their highest level in seven years.

  • June 27- Pershing Square Capital Management, led by activist investor William Ackman, and Allergan Inc have agreed that calling a special meeting in an effort to elect new board members will not trigger Allergan's so-called "poison pill" measure, settling a lawsuit, the companies said on Friday.

  • Paulson & Co said to amass large stake in Allergan Wednesday, 25 Jun 2014 | 4:53 PM ET
    A doctor draws Allergan Inc. Botox into a syringe before administering it to a patient at the offices of Marcus Facial Plastic Surgery in Redondo Beach, California

    Hedge fund Paulson & Co has amassed a large stake in Allergan and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals.

  • New York, June 25- Hedge fund Paulson& Co has amassed a large stake in Allergan Inc of more than 6 million shares and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals Inc, people familiar with the matter on Wednesday.

  • Early movers: MU, AAPL, DF, MCRS & more Tuesday, 24 Jun 2014 | 7:50 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Insider trading: How rogue is it? Monday, 23 Jun 2014 | 1:41 PM ET

    The authors of the recent study on insider trading that had Wall Street abuzz go a step further on exactly how rogue it is.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire flagged the promise of existing and new drugs on Monday as evidence that AbbVie's $46 billion offer undervalued the company, the latest British firm to be targeted by a U.S. group seeking lower taxes.

  • Allergan rejects Valeant's takeover bid...again Monday, 23 Jun 2014 | 10:53 AM ET
    A doctor draws Allergan Inc. Botox into a syringe before administering it to a patient at the offices of Marcus Facial Plastic Surgery in Redondo Beach, California

    Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.

  • June 23- Allergan Inc on Monday advised investors not to sell their shares to Valeant Pharmaceuticals International which launched a hostile takeover offer for the California- based Botox maker last week, saying it was "grossly inadequate."

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire flagged the promise of existing and new drugs on Monday as evidence that AbbVie's $46 billion offer undervalued the company, the latest British firm to be targeted by a U.S. group seeking lower taxes.

  • June 23- Allergan Inc on Monday advised investors not to sell their shares to Valeant Pharmaceuticals International which launched a hostile takeover offer for the California- based Botox maker last week, saying it was "grossly inadequate."